Led · Series A · Nov 2025

Find Your Grind offers a digital platform that guides middle- and high-school students through self-assessment, interactive lessons, mentor videos, and an AI-powered “Reflective Coach” to uncover career options beyond conventional professions. The curriculum is built around four competencies—self-awareness, career awareness, social awareness, and action awareness—and includes a Lifestyle Assessment that matches users to three lifestyle archetypes such as entertainer, creator, or humanitarian. Students receive personalized post-graduation plans and can attend workforce-development events like lifestyle fairs for hands-on exposure. The platform features high-profile mentors including Tony Hawk, Tony Hoffman, and will.i.am who share pragmatic career advice. To date, the company reports helping 100,000 students and is piloting its first city-wide program in Oklahoma City, with ambitions to roll out additional U.S. programs. Founder Nick Gross aims to reach more than one million students as the service scales. Financially, Find Your Grind has raised a total of $8 million, including the newly closed Series A round, to fund nationwide expansion of its career-readiness offerings.

Led · Series A · Mar 2025

Wheeler Bio is a contract development and manufacturing organization (CDMO) built on its Modular CMC scientific platform, focused on accelerating antibody-based therapeutic candidates from discovery into clinical trials. It provides integrated services including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, technology transfer, and cGMP manufacturing. The company emphasizes a customer-intimate approach to build robust CMC packages vital for regulatory filings and ongoing manufacturing. Wheeler plans to broaden capabilities, expand its partner base and team, and is planning a 52,000 square-foot large-scale biologics manufacturing facility adjacent to a biomanufacturing workforce training center at Convergence in the Oklahoma City Innovation District. The company is headquartered in Oklahoma City and cites regional advantages such as lower business costs and a growing biomanufacturing workforce. The recent financing is intended to fund these expansion and capability-build efforts. Wheeler Bio is an Oklahoma City-based contract development and manufacturing organization (CDMO) focused on the gene-to-IND supply chain. Its primary product is Portable CMC, an open-source "CMC middleware" that integrates discovery CROs and CDMOs to streamline translational steps. Portable CMC includes a complement of integrated development services, including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, and technology transfer into CGMP production. The platform also enhances business integrations that speed up translational steps while lowering technical, regulatory, and business risks. Wheeler Bio plans to use the $31M Series A to complete its CGMP cell banking and 500 L drug substance manufacturing facility in The Ziggurat in downtown Oklahoma City. Leadership includes CEO Dr. Jesse McCool, Chief Development Officer Dr. Brian Berquist, and Christian Kanady. Wheeler Bio offers Portable CMC™, a platform that integrates with preclinical discovery to accelerate the discovery-to-IND path. Portable CMC is designed to provide faster, easier, and more predictable tech transfer and clinical supply by partnering with preclinical CROs and antibody drug developers. The company has an initial focus on antibody therapeutics and is partnered with Alloy Therapeutics to extend discovery offerings into IND-enabling manufacturing. Wheeler Bio is headquartered in Oklahoma City and operates pilot labs inside Alloy Therapeutics’ Boston facility. It closed a $14M Seed financing to expand its team and make Portable CMC more broadly available. Scientific and operational leadership for Portable CMC is led by CTO Dr. Stephen Hamilton, and the company emphasizes speed, predictability, and shared success with CDMO and CRO partners.

Participated · Seed · Jan 2024

TARA Mind develops a clinician-guided, data-driven collaborative care platform to deliver ketamine-assisted therapy (KAT) and other emerging mental health treatments as an employer-covered benefit. The company focuses on individuals with treatment-resistant mental health disorders and aims to integrate personalized, evidence-based care into self-funded employer benefit plans. TARA Mind maintains a structured real-world evidence dataset to support outcomes and decision-making and emphasizes measurable ROI for employers via reduced medical costs, lower absenteeism, and improved productivity. The firm positions itself as a first mover in the employer benefit space for psychedelic-assisted therapies and seeks to expand affordable access nationwide. Founded in 2022 by Marcus Capone with involvement from Red Cell Partners (Grant Verstandig and Dr. Yisroel Brumer), TARA Mind is organized as a public benefit corporation and is scaling its provider network and employer partnerships. The company recently completed a seed financing round to support that expansion. TARA Mind, founded in 2022, is a Public Benefit Corporation emerging from stealth to expand safe, affordable, and effective access to psychedelic-assisted therapy (PAT). The company has built a network of vetted PAT providers across the US and abroad and is developing proprietary digital measurement-based care tools to ensure safety, optimize outcomes, and enable data-driven, value-based reimbursement. It has codified The TARA Mind Way™ and PTIM™, a clinician-guided framework of Preparation, Treatment, Integration, and Monitoring, to guarantee wraparound services and standardize care. TARA Mind is working with early-adopter employers to add its provider network as a supplemental benefit to existing health plans to reduce equity barriers and drive employer ROI. The company has convened medical advisors from institutions including Harvard, Stanford, and Mount Sinai to help define standards of care. Red Cell Partners announced $3 million in pre-seed funding to fuel the company’s mission and product development.

Participated · Series A · Oct 2023

Nucleus RadioPharma manufactures radiopharmaceuticals and manages the time-sensitive logistics required to deliver those radioactive cancer therapies to hospitals before they decay. Founded in late 2022 and launched in 2023 with a $56 million Series A, the company opened its Rochester manufacturing facility on the Mayo Clinic campus and plans a second regional hub outside Philadelphia. Its strategy centers on expanding regional manufacturing capacity to address supply-chain bottlenecks caused by short half-lives of radioactive isotopes. The recent $50 million financing from OrbiMed will fund further expansion at Rochester and construction of the Philadelphia-area site. Nucleus currently employs 56 full-time staff and is hiring as it ramps toward full operations, aiming to have the new regional center operational by 2028.

Participated · Series B · Sep 2022

Firehawk Aerospace, founded in 2020, designs and manufactures solid rocket motors, base bleed motors, hybrid rocket engines, and 3D-printed propellant. The company emphasizes additive manufacturing and digital process control to transform energetics production and reduce fragility in supply chains. It has developed a robust patent portfolio and has demonstrated credibility with leading aerospace and defense stakeholders, including a successful GMLRS-class rocket flight test under an Army SBIR Phase III with the Army Applications Laboratory. Firehawk aims to scale production throughput and manufacturing infrastructure to meet growing Department of War and prime contractor demand for domestic munitions capacity. The company positions itself as a reliable domestic supplier within the U.S. defense industrial base and is pursuing expanded delivery timelines and increased production at scale.